AR049564A1 - Metodos para la evaluacion y tratamiento del cancer - Google Patents

Metodos para la evaluacion y tratamiento del cancer

Info

Publication number
AR049564A1
AR049564A1 ARP050102730A ARP050102730A AR049564A1 AR 049564 A1 AR049564 A1 AR 049564A1 AR P050102730 A ARP050102730 A AR P050102730A AR P050102730 A ARP050102730 A AR P050102730A AR 049564 A1 AR049564 A1 AR 049564A1
Authority
AR
Argentina
Prior art keywords
patient
fti
treatment
determined
farnesyl transferase
Prior art date
Application number
ARP050102730A
Other languages
English (en)
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of AR049564A1 publication Critical patent/AR049564A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Métodos para el tratamiento de pacientes con cáncer y, preferentemente, con una malignidad hematologica, que incluyen analizar los perfiles de expresion génica y/o marcadores moleculares de un paciente para determinar la probabilidades de que el paciente responda al tratamiento con inhibidores de la farnesil transferasa (FTI) y, optativamente, otros agentes terapéuticos. Los métodos son, asimismo, para monitorear la terapia del paciente y para seleccionar un curso terapéutico. Se presentan los genes modulados en la respuesta al tratamiento con FTI y se los utiliza para la formulacion de los perfiles. Reivindicacion 1: Un método para determinar si un paciente ha de responder al tratamiento con un inhibidor de la farnesil transferasa (FTI) mediante el análisis de la presencia o expresion del oncogén LBC (SEC. ID. No. 2). Reivindicacion 27: Artículos para evaluar la eficacia del tratamiento de un paciente con un inhibidor de la farnesil transferasa (FTI) que comprende un medio con el cual se determinan los perfiles de expresion génica del paciente indicativos de la respuesta al FTI. Reivindicacion 39: El uso de un inhibidor de la farnesil transferasa (FTI) para la preparacion de un medicamento para tratar a un paciente en quien ya se ha determinado o está por determinarse que el oncogén LBC (SEC. ID. No. 2) está ausente o no se expresa. Reivindicacion 41: Un kit de diagnostico para analizar una muestra de un paciente, por lo cual se determina la presencia o expresion del oncogén LBC (SEC. ID. No. 2).
ARP050102730A 2004-07-01 2005-06-30 Metodos para la evaluacion y tratamiento del cancer AR049564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/883,436 US20050003422A1 (en) 2003-07-01 2004-07-01 Methods for assessing and treating cancer

Publications (1)

Publication Number Publication Date
AR049564A1 true AR049564A1 (es) 2006-08-16

Family

ID=35058443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102730A AR049564A1 (es) 2004-07-01 2005-06-30 Metodos para la evaluacion y tratamiento del cancer

Country Status (14)

Country Link
US (1) US20050003422A1 (es)
EP (1) EP1611890B1 (es)
JP (1) JP2006014739A (es)
KR (1) KR20060048684A (es)
CN (1) CN1721553A (es)
AR (1) AR049564A1 (es)
AT (1) ATE440604T1 (es)
AU (1) AU2005202520A1 (es)
BR (1) BRPI0502433A (es)
CA (1) CA2512493A1 (es)
DE (1) DE602005016189D1 (es)
DK (1) DK1611890T3 (es)
MX (1) MXPA05007207A (es)
PT (1) PT1611890E (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0503418A (pt) * 2004-05-06 2006-04-11 Johnson & Johnson prognóstico para malignidade hematológica
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
CA2680909A1 (en) * 2007-03-12 2008-09-18 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
CA2804937C (en) * 2008-03-21 2013-11-19 Bauer Hockey Corp. Helmet for a hockey or lacrosse player
PT3301446T (pt) * 2009-02-11 2020-07-14 Caris Mpi Inc Perfilagem molecular de tumores
EP2598874B1 (en) * 2010-07-28 2018-10-24 Janssen Diagnostics, LLC Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
US20190119758A1 (en) * 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MY200746A (en) * 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US20210231666A1 (en) * 2018-06-06 2021-07-29 La Jolla Institute For Immunology Cd33 monocytes as a biomarker

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
TR199800825T2 (xx) 1995-12-08 1998-08-21 Janssen Pharmaceutica N.V. Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2001505548A (ja) 1996-12-20 2001-04-24 トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” 凍結乾燥ハイドロクロライド−１β，１０β−エポキシ−１３−ジメチルアミノ−グアヤ−３（４）−エン−６，１２−オリドの生成方法および装置
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
KR20040065524A (ko) * 2001-10-30 2004-07-22 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 백혈병을 검사 및 치료하는 방법
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia

Also Published As

Publication number Publication date
DE602005016189D1 (de) 2009-10-08
EP1611890A1 (en) 2006-01-04
MXPA05007207A (es) 2006-05-22
ATE440604T1 (de) 2009-09-15
US20050003422A1 (en) 2005-01-06
JP2006014739A (ja) 2006-01-19
PT1611890E (pt) 2009-09-29
DK1611890T3 (da) 2009-11-16
KR20060048684A (ko) 2006-05-18
EP1611890B1 (en) 2009-08-26
CA2512493A1 (en) 2006-01-01
BRPI0502433A (pt) 2006-04-04
CN1721553A (zh) 2006-01-18
AU2005202520A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
AR049564A1 (es) Metodos para la evaluacion y tratamiento del cancer
AR048945A1 (es) Pronostico para leucemia mieloide cronica
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
DE602004031405D1 (de) Marker zur Prognose der Reaktion auf Therapie bzw. der Überlebensrate von Brustkrebspatienten
PA8537401A1 (es) Diaminotiazoles
WO2005000091A3 (en) Method and apparatus for detecting ischemia
PL1889920T3 (pl) Sposób identyfikacji związków do terapii antynowotworowej in vitro
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
AR032917A1 (es) Metodo para determinar la expresion de genes de dihidropirimidina deshidrogenasa
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
ATE373725T1 (de) Methoden zur feststellung von akute myeloischen leukämie
Akýsýk et al. CD44 variant exons in leukemia and lymphoma
JP2005530518A5 (es)
AR056125A1 (es) Procedimiento para el diagnostico de tromboembolias y cardiopatias isquemicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure